All In Biotech

Drug Trial Radar · NCT00724815

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

The Efficacy and Tolerability of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled Study

Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 530 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

530

Actual

Start

Jan 2009

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
NuPathe Inc.Industry
Sponsor type
Industry
First posted
Jul 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation. Key secondary objectives included: 1. The proportion of subjects who were nausea free at two hours after patch activation. 2. The proportion of subjects who were photophobia free at two hours after patch activation. 3. The proportion of subjects who were phonophobia free at two hours after patch activation.

Conditions

  • Migraine Disorders

Interventions

  • NP101 - Sumatriptan iontophoretic transdermal patchDrug

    Sumatriptan iontophoretic transdermal patch

  • PlaceboDrug

    NP101 Placebo iontophoretic transdermal patch

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain Free at Two HoursTime frame: 2 hours post patch activation

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Newport Beach, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Fairfield, Connecticut

  • Site not named

    Ocala, Florida

  • Site not named

    Palm Beach Gardens, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Springfield, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Mount Vernon, New York

  • Site not named

    Plainview, New York

  • Site not named

    Greensboro, North Carolina

  • Site not named

    West Chester, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Wynnewood, Pennsylvania

  • Site not named

    Memphis, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Alexandria, Virginia

  • Site not named

    Virginia Beach, Virginia

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.